Israeli biopharmaceutical firm Mileutis has announced the successful conclusion of a clinical trial involving more than 500 cows across seven distinct dairy farms in Israel. The study focused on evaluating the efficacy of Imilac™️, the company's proprietary biological solution designed as a substitute for antibiotics in treating livestock. The promising results indicate not only that Imilac™️ can supplant the need for antibiotics but also enhance the quality and nutritional content of milk.
Mastitis, an inflammatory condition, poses a significant health risk to dairy cows. Currently, the prevention and treatment of mastitis heavily rely on antibiotics, contributing to the troubling rise in antibiotic-resistant bacteria. Imilac™️ offers an alternative by effectively treating and preventing mastitis without antibiotic intervention. The clinical trials suggest that this innovation could lead the dairy industry toward a more sustainable future. Mileutis estimates that the adoption of Imilac™️, in conjunction with other technologies in development, could reduce antibiotic use in dairy farming by up to 90%.
Mileutis clinical trials involving more than 500 dairy cows showed milk sourced from cows using Imilac had a 7.2% increase in protein content and a 4% increase in fat content.
— DairyProcessing (@DairyProcessing) August 21, 2023
- More details 🔽https://t.co/0cNwk7ZiCR#dairy #milk #dairyindustry
The multi-year experiment aimed to compare the quality and quantity of milk produced by cows treated with Imilac™️ against those treated conventionally with antibiotics. The trial spanned diverse geographic locations in Israel, ranging from Kibbutz Yotvata and Hiel in the South, to Moshav Kfar Vitkin in Emek Hefer, and extending to Emek Ma'ana in the northern regions. Two of Israel's largest milk producers, Strauss and Tnuva, source their milk from these farms. The study corroborated Mileutis' objective to diminish antibiotic usage in the dairy industry.
Significantly, cows treated with Imilac™️ showed a marked increase in milk yield during the 305 days of lactation following the treatment. The milk production surged by 957 kg (8.6%) per cow, achieved entirely through biological means, devoid of hormones or antibiotics. Moreover, the study found an improvement in milk quality, with a 7.2% increase in protein content and a 4% rise in milk fat.
David Javier Iskovic, the CEO and co-founder of Mileutis, remarked, "Beyond the clear benefits to the health and welfare of the cows, there are substantial implications for the profitability of dairy farmers. This could result in more cost-effective milk pricing for consumers, aligning with the growing global demand for dairy products. The strides we've made could have an unprecedented impact on not just the dairy sector but also on consumer health and environmental sustainability."
New trial: Mileutis reduces antibiotic use in dairy cows
— Feed & Additive Magazine (@feedandadditive) August 11, 2023
𝗖𝗹𝗶𝗰𝗸 𝘁𝗼 𝗿𝗲𝗮𝗱 𝗺𝗼𝗿𝗲:👉 https://t.co/SE02eWhVSe#animalhealth #animalnutrition #dairycows #dairyfarms #dairyindustry #dairyproduction #dairyproducts #Mileutis
In summary, Mileutis' groundbreaking clinical trial has far-reaching implications, promising a future where antibiotics are no longer a staple in livestock healthcare. By paving the way for healthier, more sustainably produced milk, Imilac™️ stands as a testament to the benefits of integrating biotechnology into traditional farming practices.
